<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0106257507
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EDYST 20 MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        50.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="rtl" style="direction:rtl">&nbsp;</p><div style="direction:ltr"><span style="text-align:unset">Pharmacotherapeutic group:</span></div><div style="direction:ltr"><span style="text-align:unset">Edyst&reg; contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors.</span></div><div style="direction:ltr"><span style="text-align:unset">Therapeutic indications:</span></div><div style="direction:ltr"><span style="text-align:unset">Edyst&reg; is a treatment for adult men with erectile dysfunction. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. Edyst&reg; has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity.</span></div><div style="direction:ltr"><span style="text-align:unset">Following sexual stimulation Edyst&reg; works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. The result of this is improved erectile function. Edyst&reg; will not help you if you do not have erectile dysfunction.</span></div><div style="direction:ltr"><span style="text-align:unset">It is important to note that Edyst&reg; does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction</span></div>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not take Edyst&reg; if you:<br />-Are allergic to tadalafil or any of the other ingredients of this medicine.<br />-Are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). Edyst&reg; has been shown to increase the effects of these medicines. If you are taking any form of nitrate or are unsure tell your doctor.<br />-Have serious heart disease or recently had a heart attack within the last 90 days.<br />-Recently had a stroke within the last 6 months.<br />-Have low blood pressure or uncontrolled high blood pressure.<br />-Ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.<br />-Are taking riociguat. This drug is used to treat pulmonary arterial hypertension<br />(i.e., high blood pressure in the lungs) and chronic thromboembolic<br />pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Edyst&reg;, have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.<br />b. Take special care with Edyst&reg;<br />Talk to your doctor before taking Edyst&reg;.<br />-Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. If you have a heart problem you should tell your doctor.<br />Before taking the tablets, tell your doctor if you have:<br />-Sickle cell anaemia (an abnormality of red blood cells).<br />-Multiple myeloma (cancer of the bone marrow).<br />-Leukaemia (cancer of the blood cells).<br />-Any deformation of your penis.<br />-A serious liver problem.<br />-A severe kidney problem.<br />It is not known if Edyst&reg; is effective in patients who have had:<br />-Pelvic surgery.<br />-Removal of all or part of the prostate gland in which nerves of the prostate<br />are cut (radical non nerve-sparing prostatectomy).<br />If you experience sudden decrease or loss of vision, stop taking<br />Edyst&reg; and contact your doctor immediately.<br />Decreased or sudden hearing loss has been noted in some patients taking tadalafil. Although it is not known if the event is directly related to tadalafil, if you experience decreased or sudden hearing loss, stop taking Edyst&reg; and contact your doctor immediately.<br />Edyst&reg; is not intended for use by women.<br />Children and adolescents<br />Edyst&reg; is not intended for use by children and adolescents under the age of 18.<br />c. Taking other medicines, herbal or dietary supplements<br />Tell your doctor if you are taking, have recently taken or might take any other medicines<br />-Do not take Edyst&reg; if you are already taking nitrates.<br />Some medicines may be affected by Edyst&reg; or they may affect how well Edyst&reg; will work. Tell your doctor or pharmacist if you are already taking:<br />-An alpha blocker (used to treat high blood pressure or urinary symptoms<br />associated with benign prostatic hyperplasia).<br />-Other medicines to treat high blood pressure.<br />-Riociguat.<br />-A 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).<br />-Medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for<br />-Treatment of AIDS or HIV infection.<br />-Phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).<br />-Rifampicin, erythromycin, clarithromycin or itraconazole.<br />-Other treatments for erectile dysfunction.<br />d. Taking Edyst&reg; with drink and alcohol<br />Drinking alcohol may affect your ability to get an erection and may temporarily<br />lower your blood pressure. If you have taken or are planning to take Edyst&reg;, avoid excessive drinking (blood alcohol level of 0.08 % or greater), since this may increase the risk of dizziness when standing up. Grapefruit juice may affect how well Edyst&reg; will work and should be taken with caution. Talk to your doctor for further information.<br />e. Pregnancy and breast-feeding:<br />Edyst&reg; is not intended for use by women.<br />f. Driving and using machines<br />Check carefully how you react to the tablets before driving or using machines due to some men taking Edyst&reg; in studies have reported dizziness.<br />g. Important information about some of the ingredients of Edyst&reg; Tablets<br />If you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not take Edyst&reg; if you:<br />-Are allergic to tadalafil or any of the other ingredients of this medicine.<br />-Are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). Edyst&reg; has been shown to increase the effects of these medicines. If you are taking any form of nitrate or are unsure tell your doctor.<br />-Have serious heart disease or recently had a heart attack within the last 90 days.<br />-Recently had a stroke within the last 6 months.<br />-Have low blood pressure or uncontrolled high blood pressure.<br />-Ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.<br />-Are taking riociguat. This drug is used to treat pulmonary arterial hypertension<br />(i.e., high blood pressure in the lungs) and chronic thromboembolic<br />pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Edyst&reg;, have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.<br />b. Take special care with Edyst&reg;<br />Talk to your doctor before taking Edyst&reg;.<br />-Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. If you have a heart problem you should tell your doctor.<br />Before taking the tablets, tell your doctor if you have:<br />-Sickle cell anaemia (an abnormality of red blood cells).<br />-Multiple myeloma (cancer of the bone marrow).<br />-Leukaemia (cancer of the blood cells).<br />-Any deformation of your penis.<br />-A serious liver problem.<br />-A severe kidney problem.<br />It is not known if Edyst&reg; is effective in patients who have had:<br />-Pelvic surgery.<br />-Removal of all or part of the prostate gland in which nerves of the prostate<br />are cut (radical non nerve-sparing prostatectomy).<br />If you experience sudden decrease or loss of vision, stop taking<br />Edyst&reg; and contact your doctor immediately.<br />Decreased or sudden hearing loss has been noted in some patients taking tadalafil. Although it is not known if the event is directly related to tadalafil, if you experience decreased or sudden hearing loss, stop taking Edyst&reg; and contact your doctor immediately.<br />Edyst&reg; is not intended for use by women.<br />Children and adolescents<br />Edyst&reg; is not intended for use by children and adolescents under the age of 18.<br />c. Taking other medicines, herbal or dietary supplements<br />Tell your doctor if you are taking, have recently taken or might take any other medicines<br />-Do not take Edyst&reg; if you are already taking nitrates.<br />Some medicines may be affected by Edyst&reg; or they may affect how well Edyst&reg; will work. Tell your doctor or pharmacist if you are already taking:<br />-An alpha blocker (used to treat high blood pressure or urinary symptoms<br />associated with benign prostatic hyperplasia).<br />-Other medicines to treat high blood pressure.<br />-Riociguat.<br />-A 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).<br />-Medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for<br />-Treatment of AIDS or HIV infection.<br />-Phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).<br />-Rifampicin, erythromycin, clarithromycin or itraconazole.<br />-Other treatments for erectile dysfunction.<br />d. Taking Edyst&reg; with drink and alcohol<br />Drinking alcohol may affect your ability to get an erection and may temporarily<br />lower your blood pressure. If you have taken or are planning to take Edyst&reg;, avoid excessive drinking (blood alcohol level of 0.08 % or greater), since this may increase the risk of dizziness when standing up. Grapefruit juice may affect how well Edyst&reg; will work and should be taken with caution. Talk to your doctor for further information.<br />e. Pregnancy and breast-feeding:<br />Edyst&reg; is not intended for use by women.<br />f. Driving and using machines<br />Check carefully how you react to the tablets before driving or using machines due to some men taking Edyst&reg; in studies have reported dizziness.<br />g. Important information about some of the ingredients of Edyst&reg; Tablets<br />If you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate in nature.<br />-If you experience any of the following side effects stop using the medicine<br />and seek medical help immediately:<br />-Allergic reactions including rashes (frequency uncommon).<br />-Chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon).<br />-Priapism, a prolonged and possibly painful erection after taking<br />Edyst&reg; (frequency rare). If you<br />-Have such an erection, which lasts continuously for more than 4 hours you should contact a doctor immediately.<br />-Sudden loss of vision (frequency rare).<br />Other side effects have been reported:<br />Common (seen in 1 to 10 in every 100 patients)<br />Headache, back pain, muscle aches, pain in arms and legs, facial flushing,<br />nasal congestion, and indigestion.<br />Uncommon (seen in 1 to 10 in every 1,000 patients)<br />Dizziness, stomach ache, feeling sick, being sick (vomiting), reflux, blurred vision, eye pain, difficulty in breathing, presence of blood in urine, prolonged erection, pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood pressure, nose bleeds, ringing in the ears, swelling of the hands, feet or ankles and feeling tired.<br />Rare (seen in 1 to 10 in every 10,000 patients)<br />Fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss of hearing, hives (itchy red welts on the surface of the skin), penile bleeding, presence of blood in semen and increased sweating.<br />Heart attack and stroke have also been reported rarely in men taking Edyst&reg;. Most of these men had known heart problems before taking this medicine.<br />Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported.<br />Some additional rare side effects have been reported in men taking Edyst&reg; that were not seen in clinical trials.<br />These include:<br />migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat, serious skin rashes, some disorders affecting<br />blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.<br />The side effect dizziness has been reported more frequently in men over 75 years of age taking Edyst&reg;. Diarrhoea has been reported more frequently<br />in men over 65 years of age taking Edyst&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Keep this medicine out of the sight and reach of children.<br />-Do not store above 30&deg;C, protect from moisture.<br />-Do not use Edyst&reg; F.C Tablets after the expiry date which is stated on the carton and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />-Do not use Edyst&reg; F.C Tablets if you notice description of the visible signs of deterioration.<br />-Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: tadalafil.<br />Edyst&reg; 20mg F.C Tablets: Each film coated tablet contains 20 mg Tadalafil.<br />Excipients:<br />Lactose Monohydrate, Crosscarmellose Sodium, Hydroxypropylcellulose,<br />Sodium Lauryl Sulphate, Microcrystalline Cellulose, Magnesium Stearate, Opadry White, Red Iron Oxide &amp; Yellow Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form is Film coated tablets
Edyst® F.C Tablets looks like a yellow and almond shaped film-coated tablet embossed with U55 on one side and plain from the other side.
Edyst® Tablets are packed in PVC/Aclar/PVC\Aluminum blisters, in carton box with a folded leaflet, in pack size of 1, 4 & 20 F.C Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The United Pharmaceutical Mfg. Co. Ltd.<br />P.O. Box 69, Amman 11591-Jordan<br />Tel: + 962 (6) 416 2901<br />Fax: + 962 (6) 416 2905<br />E-mail: upm_info@mspharma.com<br />For any information about this medicinal product, please contact the local<br />representative of the Marketing Authorization Holder:<br />Cigalah Group<br />P.O. Box 19435, Jeddah 21435 -KSA<br />Tel: +966126136740<br />Fax: + 96626148458<br />E-mail: ihamidaddin@cigalah.com.sa<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in Feb., 2017; version number
M3-14-0972

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي إيديست على المادة الفعالة تادالافيل والذي ينتمي إلى مجموعة الأدوية التي تسمى مثبطات انزيم فوسفوديإستيريز نوع 5. إيديست هو علاج للرجال البالغين الذين يعانون من ضعف الانتصاب. عندما لا يستطيع الرجل الحصول على، أو من الصعب الحفاظ على، قضيب منتصب ومناسب للنشاط الجنسي. وقد تبين أن إيديست يحسن بشكل كبير من القدرة على الحصول على قضيب منتصب صلب مناسب للنشاط الجنسي. بعد التحفيز الجنسي، يعمل إيديست من خلال مساعدة الأوعية الدموية في القضيب الخاص بك للاسترخاء، والسماح لتدفق الدم في القضيب الخاص بك. ونتيجة لهذا يحسن وظيفة الانتصاب. لن يساعدك إيديست إذا لم تكن تعاني من ضعف الانتصاب. من المهم أن نلاحظ أن إيديست لا يعمل إذا لم يكن هناك تحفيز جنسي. سوف تحتاج أنت وشريكك إلى الانخراط في المداعبة، تماما كما لو كنت لا تأخذ دواء لعلاج ضعف الانتصاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>2. قبل القيام بتناول أو استعمال إيديست أ. لا تستعمل أقراص إيديست إذا- كان لديك حساسية تجاه تادالافيل أو لأي من المكونات الأخرى لهذا الدواء. - كنت تأخذ أي شكل من أشكال النترات العضوية أو المواد المانحة لأكسيد النيتريك مثل أميل نتريت. هي مجموعة من الأدوية &laquo;النترات&raquo; المستخدمة في علاج الذبحة الصدرية &laquo;ألم في الصدر&raquo;. قد تبين (()) بأن إيديست يزيد من آثار هذه الأدوية. إذا كنت تأخذ أي شكل من أشكال النترات أو كنت غير متأكد أخبر طبيبك.- كنت تعاني من أمراض خطيرة في القلب أو أصبت مؤخرا بأزمة قلبية خلال ال 90 يوما الماضية.- عانيت في الآونة الأخيرة من سكتة دماغية خلال ال 6 أشهر الماضية.- كنت تعاني من انخفاض ضغط الدم أو ارتفاع ضغط الدم غير المنضبط. - كنت تعاني في أي وقت مضى من فقدان الرؤية بسبب الاعتلال العصبي البصري الأمامي لنقص التروية، وهي حالة توصف بأنها &laquo;سكتة للعين.&raquo; - كنت تأخذ ريوسيغوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي أي ارتفاع ضغط الدم ) في الرئتين وارتفاع ضغط الدم الرئوي التخثري المزمن أي ارتفاع ضغط الدم في الرئتين بسبب جلطات () الدم. وقد ثبت أن مثبطات انزيم فوسفوديإستيريز نوع 5، مثل تادالافيل، تزيد من تأثيرات هذا الدواء الخافضة (للضغط. إذا كنت تأخذ ريوسيغوات أو غير متأكد أخبر طبيبك.ب. الاحتياطات عند استعمال إيديست تحدث مع طبيبك قبل أخذ إيديست . - كن على علم بأن النشاط الجنسي يحمل مخاطر محتملة للمرضى الذين يعانون من أمراض القلب لأنه يضع ضغطا إضافيا على قلبك. إذا كان لديك مشكلة في القلب يجب أن تخبر طبيبك.قبل أخذ الأقراص، أخبر طبيبك إذا كان لديك:- فقر الدم المنجلي شذوذ خلايا الدم الحمراء.()- الورم النخاعي المتعدد سرطان نخاع العظام.()- سرطان الدم سرطان خلايا الدم.()- أي تشوه في القضيب الخاص بك.- مشكلة خطيرة في الكبد.- مشكلة شديدة في الكلى.لا يعرف ما إذا كان إيديست فعال في المرضى الذين لديهم:-جراحة في الحوض. - إزالة كل أو جزء من غدة البروستات والتي تقطع فيها أعصاب غدة البروستات استئصال غدة البروستات )الجذري غير العصبي.( إذا كنت تعاني من انخفاض مفاجئ أو فقدان الرؤية، يجب التوقف عن تناول إيديست ويجب الاتصال بطبيبك على الفور. قد لوحظ انخفاض أو فقدان السمع المفاجئ في بعض المرضى الذين يتناولون تادالافيل. على الرغم من أنه ليس من المعروف ما إذا كان الحدث مرتبطا مباشرة بتادالافيل، إذا كنت تعاني من انخفاض أو فقدان للسمع مفاجئ، يجب التوقف عن تناول إيديست والاتصال بطبيبك على الفور.إيديست غير مخصص للاستخدام من قبل النساء.الأطفال والمراهقينإيديست غير مخصص للاستخدام من قبل الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما.ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائيةأخبر طبيبك إذا كنت تأخذ، قد أخذت مؤخرا أو قد تأخذ أي أدوية أخرى- لا تأخذ إيديست إذا كنت تأخذ النترات بالفعل. قد تتأثر بعض الأدوية بإيديست أو قد تؤثر على مدى نجاح إيديست. أخبر طبيبك أو الصيدلي إذا كنت تأخذ بالفعل: - مثبطات مستقبلات ألفا يستخدم لعلاج ارتفاع ضغط الدم أو الأعراض البولية المرتبطة بتضخم غدة )البروستات الحميد.(- أدوية أخرى لعلاج ارتفاع ضغط الدم.- ريوسيغوات.- مثبط 5-ألفا ريداكتاز يستخدم لعلاج تضخم غدة البروستات الحميد.()- أدوية مثل أقراص كيتوكونازول لعلاج الالتهابات الفطرية ومثبطات الأنزيم البروتيني()- علاج الإيدز أو عدوى فيروس العوز المناعي البشري.- فينوباربيتال، فينيتوين وكاربامازيبين أدوية مضادة للصرع.()- ريفامبيسين، اريثروميسين، كلاريثروميسين أو إتراكونازول.- علاجات أخرى لعلاج ضعف الانتصاب.د. إيديست مع المشروبات والكحول قد يؤثر شرب الكحول على قدرتك على الحصول على الانتصاب وقد يقلل ضغط الدم بشكل مؤقت. إذا كنت قد أخذت أو تخطط لتناول إيديست، يجب تجنب الإفراط في شرب الكحول مستوى الكحول في الدم من ) ٪0.08 أو أكثر، لأن هذا قد يزيد من خطر الدوخة عند الوقوف. ( قد يؤثر عصير الجريب فروت على كيفية عمل إيديست وينبغي أن يؤخذ بحذر. تحدث مع طبيبك للحصول على مزيد من المعلومات.ه.الحمل و الرضاعه إيديست لا يوصى باستخدامه من قبل النساء و.القيادة واستخدام الآلاتإن هذا دواء&bull;الدواء مستحضر يؤثر على صحتك واستهلاكه خلافا للتعليمات يعرضك للخطر.&bull;إتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذى صرفها لك.&bull;إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره.&bull;لاتقطع مدة العلاج المحددة لك من تلقاء نفسك.&bull;لا تكرر صرف الدواء بدون وصفة طبية. &bull;إحفظ الدواء بعيدا عن متناول الاطفال. مجلس وزراء الصحة العرب إتحاد الصيادلة العرب تحقق بعناية من كيفية تفاعلك مع الأقراص قبل القيادة أو استخدام الآلات, كان هناك تقارير حدوث الدوخة في بعض الرجال الذين يتناولون إيديست .ز. يحتوي إيديست على اللاكتوزإذا كنت تعاني من عدم تحمل لبعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>3. طريقة استعمال إإيديستدائما تناول هذا الدواء تماما كما قال لك الطبيب. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد. أقراص إيديست هي للاستخدام عن طريق الفم في الرجال فقط. يجب بلع القرص كاملا مع بعض الماء. يمكن أن تؤخذ الأقراص بغض النظر عن تناول الطعام. تبلغ الجرعة الابتدائية الموصى بها هي قرص واحد 10 ملغم قبل النشاط الجنسي. ومع ذلك، إذا كنت قد أعطيت جرعة مقدارها 20ملغم كما قرر طبيبك بأن جرعة 10ملغم هي ضعيفة جدا.يمكن أن تأخذ قرص إيديست قبل 30 دقيقة على الأقل من النشاط الجنسي.يبقى إيديست فعال حتى 36 ساعة بعد أخذ القرص. لا تأخذ إيديست أكثر من مرة في اليوم. إيديست 20ملغم هو مخصص للاستخدام قبل النشاط الجنسي المتوقع ولا ينصح به للاستخدام اليومي المستمر. من المهم أن نلاحظ أن إيديست لا يعمل إذا لم يكن هناك تحفيز جنسي. سوف تحتاج أنت وشريكك إلى الانخراط في المداعبة، تماما كما لو كنت لا تأخذ دواء لعلاج ضعف الانتصاب.أ. إذا تناولت إيديست أكثر مما يجباتصل بطبيبك. قد تواجه آثار جانبية.إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.ب. إذا نسيت تناول أقراص إيديست لا تأخذ إيديست أكثر من مره في اليوم , إيديست مخصص للاستخدام قبل النشاط الجنسي المتوقع.ج. إذا توقفت عن تناول أقراص إيديست لا يوصى بالإستعمال اليومي المستمر لأقراص إيديست</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، وإن لم يصب بها كل الاشخاص. عادة ما تكون هذه الآثار خفيفة إلى معتدلة في طبيعتها. - إذا كنت تعاني من أي من الآثار الجانبية التالية، يجب عليك التوقف عن استخدام الدواء وطلب المساعدة الطبية على الفور:- الحساسية بما في ذلك الطفح الجلدي تردد غير شائع.()- ألم في الصدر لا تستخدم النترات ولكن التمس المساعدة الطبية الفورية تردد غير مألوف.(()) - القساح، وهو انتصاب لفترات طويلة وربما يكون مؤلم بعد تناول إيديست تردد نادر. ()- اذا أصبت بمثل هذا الانتصاب، والذي يستمر لأكثر من 4 ساعات يجب عليك الاتصال بالطبيب على الفور.- فقدان مفاجئ في الرؤية تردد نادر.()قد تم الإبلاغ عن آثار جانبية أخرى:شائعة لوحظت في 1 إلى 10 في كل 100 مريض(<br />) صداع، آلام الظهر، آلام في العضلات، ألم في الذراعين والساقين، احمرار الوجه، احتقان الأنف، وعسر الهضم.غير شائعة لوحظت في 1 إلى 10 في كل 1000 مريض(<br />) دوخة، آلام في المعدة، الشعور بالمرض، القيء، ارتداد، عدم وضوح الرؤية، آلام في العين، صعوبة في التنفس، وجود الدم في البول، انتصاب لفترات طويلة، الشعور بتسارع ضربات القلب، تسارع في معدل ضربات القلب، ارتفاع ضغط الدم، انخفاض ضغط الدم، نزيف الأنف، رنين في الأذنين، تورم في اليدين والقدمين أو الكاحلين والشعور بالتعب.نادرة لوحظت في 1 إلى 10 في كل 10000 مريض(<br />) إغماء، تشنجات، فقدان الذاكرة، تورم في الجفون، احمرار العيون، انخفاض مفاجئ أو فقدان في السمع، شرى بقعة حمراء تسبب الحكة على السطح من الجلد، نزيف القضيب، وجود الدم في السائل المنوي ()وزيادة التعرق. كما تم الإبلاغ عن نوبات قلبية وسكتة دماغية بشكل نادرا في الرجال الذين يتناولون إيديست. وكان معظم هؤلاء الرجال يعانون من مشاكل في القلب قبل تناول هذا الدواء.نادرا ما تم الإبلاغ عن نقص جزئي أو مؤقت أو دائم أو فقدان في الرؤية في واحدة أو كلتا العينين.قد تم الإبلاغ عن بعض الآثار الجانبية النادرة الإضافية في الرجال الذين يتناولون إيديست. تشمل هذه: الصداع النصفي,انتفاخ بالوجه,رد فعل تحسسي خطيرمما يسبب انتفاخ في الوجه والحلق، طفح جلدي خطير، بعض الاضطرابات التي تؤثر على تدفق الدم إلى العينين، عدم انتظام ضربات القلب، الذبحة الصدرية والموت القلبي المفاجئ. قد تم الإبلاغ عن دوخة كتأثير جانبي بشكل أكثر تواترا في الرجال الأكبر من 75 عاما من العمر والذين يتناولون إيديست. قد تم الإبلاغ عن حدوث الإسهال بشكل أكثر تواترا لدى الرجال الذين تزيد أعمارهم عن 65 عاما والذين يتناولون إيديست .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-يحفظ بدرجة حرارة لا تتجاوز 30&deg;م، بعيداً عن الرطوبة والضوء. -لا تستخدم أقراص إيديست بعد تاريخ انتهاء الصلاحية تاريخ انتهاء الصلاحية الذي يرد على العبوة ()الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.-لا تستخدم أقراص إيديست إذا لاحظت مواصفات علامات التدهور المرئية. -يجب عدم التخلص من الأدوية عن طريق المياه العادمة أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: تادالافيل. إيديست20 ملغم: كل قرص مغلف يحتوي على 20ملغم تادالافيل. المكونات الاخرى: لاكتوز مونوهيدرات، كارميلوز الصوديوم المتشابك، هيدروكسي بروبيل سليلوز، دوديسيل كبريتات صوديوم، سيليلوز دقيق التبلور، إستارات المغنيسيوم، أوبادراي أبيض، أكسيد الحديد الأحمر وأكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني: أقراص مغلفة شكل أقراص إيديست هي أقراص مغلفة ذات لون أصفر وعلى شكل لوزي و منقوشة ب U55 على أحد الجوانب وفارغة من الجهة الاخرى. أقراص إيديست معبأة في أشرطة من الألومنيوم / PVC/ PVC/Aclar، في علبة كرتون مع نشرة مطوية ، في عبوات حجم 1، 4 و 20 أقراص مغلفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني: أقراص مغلفة شكل أقراص إيديست هي أقراص مغلفة ذات لون أصفر وعلى شكل لوزي و منقوشة ب U55 على أحد الجوانب وفارغة من الجهة الاخرى. أقراص إيديست معبأة في أشرطة من الألومنيوم / PVC/ PVC/Aclar، في علبة كرتون مع نشرة مطوية ، في عبوات حجم 1، 4 و 20 أقراص مغلفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على هذه النشره بتاريخ Feb., 2017؛ رقم النسخة: 0972-14-M3
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Edyst® 20mg Film Coated Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Amount (mg)/one tablet 	Function 	Material Name 	%w/w
Tadalafil	Active Material 	20.0*	5.7
Core In-active ingredients:
Lactose Monohydrate	Diluent	233.1	66.6
Crosscarmellose sodium	Disintegrant	17.5	5.0
Hydroxypropylcellulose	Binder	3.5	1.0
Sodium Lauryl sulphate	Wetting agent	7.0	2.0
Microcrystalline Cellulose	Diluent	67.15*	19.2
Magnesium Stearate	Lubricant	1.75	0.5
Total before coating 	350	
*Material Quantity may slightly vary according to potency and water content of the active ingredient.

Film coating In-Active ingredients:
Opadry White 	Film Coating material	10.5
Red Iron Oxide	Coloring agent	0.0053
Yellow Iron Oxide	Coloring agent	1.0
Total after coating	361.5

For a full list of excipients, see section 6.1 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets
Edyst® 20mg F.C. Tablets: Yellow and almond shaped film coated tablet, embossed with ‘U55’ on one side and plain from the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult males.</p><p>In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required.</p><p>Tadalafil is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration: Orally.</strong></p><p><em>Erectile dysfunction in adult Men</em></p><p>In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or without food.</p><p>In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be tried. It may be taken at least 30 minutes prior to sexual activity.</p><p>The maximum dose frequency is once per day.</p><p>Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use.</p><p>In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician&#39;s judgement.</p><p>In these patients, the recommended dose is 5mg taken once a day at approximately the same time of day. The appropriateness of continued use of the daily regimen should be reassessed periodically.</p><p><em>Benign prostatic hyperplasia in adult men (tadalafil 5 mg only)</em></p><p>The recommended dose is 5 mg, taken at approximately the same time every day with or without food. For adult men being treated for both benign prostatic hyperplasia and erectile dysfunction the recommended dose is also 5 mg taken at approximately the same time every day.</p><p><u>Special Populations</u></p><p><em>Elderly Men</em></p><p>Dose adjustments are not required in elderly patients.</p><p><em>Men with Renal Impairment</em></p><p>Dose adjustments are not required in patients with mild to moderate renal impairment. For patients with severe renal impairment, 10 mg is the maximum recommended dose.</p><p><em>Men with Hepatic Impairment</em></p><p>For the treatment of erectile dysfunction using on-demand tadalafil the recommended dose of tadalafil is 10 mg taken prior to anticipated sexual activity and with or without food. There is limited clinical data on the safety of tadalafil in patients with severe hepatic impairment (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10mg of tadalafil to patients with hepatic impairment.</p><p>Once-a-day dosing both for the treatment of erectile dysfunction and benign prostatic hyperplasia has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.</p><p><em>Men with Diabetes</em></p><p>Dose adjustments are not required in diabetic patients.</p><p><em>Paediatric population</em></p><p>There is no relevant use of tadalafil in the paediatric population with regard to the treatment of erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
Tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated.
Tadalafil must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
The following groups of patients with cardiovascular disease were not included and the use of tadalafil is therefore contraindicated:
-	Patients with myocardial infarction within the last 90 days,
-	Patients with unstable angina or angina occurring during sexual intercourse,
-	Patients with New York Heart Association Class 2 or greater heart failure in the last 6 months,
-	Patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension,
-	Patients with a stroke within the last 6 months.
Tadalafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Before treatment with tadalafil</u></p><p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction or benign prostatic hyperplasia and determine potential underlying causes, before pharmacological treatment is considered.</p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure and as such potentiates the hypotensive effect of nitrates.</p><p>The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following an appropriate medical assessment. It is not known if tadalafil is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy.</p><p>Tadalafil 5 mg - Prior to initiating treatment with tadalafil for benign prostatic hyperplasia patients should be examined to rule out the presence of carcinoma of the prostate and carefully assessed for cardiovascular conditions.</p><p><u>Cardiovascular</u></p><p>Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations and tachycardia, have been reported either. Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not possible to definitively determine whether these events are related directly to these risk factors, to tadalafil, to sexual activity, or to a combination of these or other factors.</p><p>Tadalafil in patients receiving concomitant antihypertensive medicinal products, tadalafil may induce a blood pressure decrease. When initiating daily treatment with tadalafil, appropriate clinical considerations should be given to a possible dose adjustment of the antihypertensive therapy.</p><p>In patients who are taking alpha<sub>1</sub>&nbsp;blockers, concomitant administration of tadalafil may lead to symptomatic hypotension in some patients. The combination of tadalafil and doxazosin is not recommended.</p><p><u>Vision</u></p><p>Visual defects and cases of NAION have been reported in connection with the intake of tadalafil and other PDE5 inhibitors. The patient should be advised that in case of sudden visual defect, he should stop taking tadalafil and consult a physician immediately.</p><p><u>Renal and hepatic impairment </u></p><p>Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability to influence clearance by dialysis, once-a-day dosing of tadalafil is not recommended in patients with severe renal impairment.</p><p>There is limited clinical data on the safety of single-dose administration of tadalafil in patients with severe hepatic insufficiency (Child-Pugh Class C). Once-a-day administration has not been evaluated in patients with hepatic insufficiency. If tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.</p><p><u>Hepatic impairment </u></p><p>There is limited clinical data on the safety of single-dose administration of tadalafil in patients with severe hepatic insufficiency (Child-Pugh Class C). If tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.</p><p><u>Priapism and anatomical deformation of the penis</u></p><p>Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.</p><p>Tadalafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p><u>Use with CYP3A4 inhibitors</u></p><p>Caution should be exercised when prescribing tadalafil to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined.</p><p><u>Tadalafil and other treatments for erectile dysfunction</u></p><p>The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. The patients should be informed not to take tadalafil in such combinations.</p><p><u>Lactose</u></p><p>Tadalafil contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically relevant interactions at higher doses cannot be completely ruled out.</p><p><u>Effects of Other Substances on tadalafil</u></p><p><em>Cytochrome P450 inhibitors</em></p><p>Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole (200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and C<sub>max</sub>&nbsp;by 15%, relative to the AUC and C<sub>max</sub>&nbsp;values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg) exposure (AUC) 4-fold and C<sub>max</sub>&nbsp;by 22%. Ritonavir, a protease inhibitor (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg) exposure (AUC) 2-fold with no change in C<sub>max</sub>. Although specific interactions have not been studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with caution, as they would be expected to increase plasma concentrations of tadalafil. Consequently, the incidence of the adverse reactions listed in section 4.8 might be increased.</p><p><em>Transporters</em></p><p>The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known. Therefore, there is the potential of drug interactions mediated by inhibition of transporters.</p><p><em>Cytochrome P450 inducers</em></p><p>A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil.</p><p><u>Effects of tadalafil on Other Medicinal Products</u></p><p><em>Nitrates</em></p><p>Tadalafil was shown to augment the hypotensive effects of nitrates. Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated. In a patient prescribed any dose of tadalafil (5 mg- 20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of tadalafil before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring.</p><p><em>Anti-hypertensives (including calcium channel blockers)</em></p><p>The co-administration of doxazosin (4 and 8 mg daily) and tadalafil 20 mg as a single dose increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this combination is not recommended.</p><p>Caution should be exercised when using tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and progressively adjusted.</p><p>In clinical pharmacology, the potential for tadalafil to augment the hypotensive effects of antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products, including calcium-channel blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10 mg, except with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of blood pressure control. In this regard whose blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy subjects. In whose blood pressure was not controlled, the reduction was greater, although this reduction was not associated with hypotensive symptoms in the majority of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a blood pressure decrease, which (with the exception of alpha-blockers) is, in general, minor and not likely to be clinically relevant. Analysis showed no difference in adverse events in patients taking tadalafil with or without antihypertensive medicinal products. However, appropriate clinical advice should be given to patients regarding a possible decrease in blood pressure when they are treated with antihypertensive medicinal products.</p><p><em>Riociguat</em></p><p>Riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favorable clinical effect of the combination. Concomitant use of riociguat with PDE5 inhibitors, including tadalafil, is contraindicated.</p><p><em>5- Alpha reductase inhibitors</em></p><p>Caution should be exercised when tadalafil is co-administered with 5-ARIs.</p><p><em>CYP1A2 substrates (e.g. theophylline)</em></p><p>When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase inhibitor), there was no pharmacokinetic interaction. The only pharmacodynamic effect was a small increase in heart rate. Although this effect is minor and was of no clinical significance, it should be considered when co-administering these medicinal products.</p><p><em>Ethinylestradiol&nbsp;and terbutaline</em></p><p>Tadalafil has been demonstrated to produce an increase in the oral bioavailability of ethinylestradiol; a similar increase may be expected with oral administration of terbutaline, although the clinical consequence of this is uncertain.</p><p><em>Alcohol</em></p><p>Alcohol concentrat</p><p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically relevant interactions at higher doses cannot be completely ruled out.</p><p><u>Effects of Other Substances on tadalafil</u></p><p><em>Cytochrome P450 inhibitors</em></p><p>Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole (200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and C<sub>max</sub>&nbsp;by 15%, relative to the AUC and C<sub>max</sub>&nbsp;values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg) exposure (AUC) 4-fold and C<sub>max</sub>&nbsp;by 22%. Ritonavir, a protease inhibitor (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg) exposure (AUC) 2-fold with no change in C<sub>max</sub>. Although specific interactions have not been studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with caution, as they would be expected to increase plasma concentrations of tadalafil. Consequently, the incidence of the adverse reactions listed in section 4.8 might be increased.</p><p><em>Transporters</em></p><p>The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known. Therefore, there is the potential of drug interactions mediated by inhibition of transporters.</p><p><em>Cytochrome P450 inducers</em></p><p>A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil.</p><p><u>Effects of tadalafil on Other Medicinal Products</u></p><p><em>Nitrates</em></p><p>Tadalafil was shown to augment the hypotensive effects of nitrates. Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated. In a patient prescribed any dose of tadalafil (5 mg- 20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of tadalafil before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring.</p><p><em>Anti-hypertensives (including calcium channel blockers)</em></p><p>The co-administration of doxazosin (4 and 8 mg daily) and tadalafil 20 mg as a single dose increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this combination is not recommended.</p><p>Caution should be exercised when using tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and progressively adjusted.</p><p>In clinical pharmacology, the potential for tadalafil to augment the hypotensive effects of antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products, including calcium-channel blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10 mg, except with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of blood pressure control. In this regard whose blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy subjects. In whose blood pressure was not controlled, the reduction was greater, although this reduction was not associated with hypotensive symptoms in the majority of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a blood pressure decrease, which (with the exception of alpha-blockers) is, in general, minor and not likely to be clinically relevant. Analysis showed no difference in adverse events in patients taking tadalafil with or without antihypertensive medicinal products. However, appropriate clinical advice should be given to patients regarding a possible decrease in blood pressure when they are treated with antihypertensive medicinal products.</p><p><em>Riociguat</em></p><p>Riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favorable clinical effect of the combination. Concomitant use of riociguat with PDE5 inhibitors, including tadalafil, is contraindicated.</p><p><em>5- Alpha reductase inhibitors</em></p><p>Caution should be exercised when tadalafil is co-administered with 5-ARIs.</p><p><em>CYP1A2 substrates (e.g. theophylline)</em></p><p>When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase inhibitor), there was no pharmacokinetic interaction. The only pharmacodynamic effect was a small increase in heart rate. Although this effect is minor and was of no clinical significance, it should be considered when co-administering these medicinal products.</p><p><em>Ethinylestradiol&nbsp;and terbutaline</em></p><p>Tadalafil has been demonstrated to produce an increase in the oral bioavailability of ethinylestradiol; a similar increase may be expected with oral administration of terbutaline, although the clinical consequence of this is uncertain.</p><p><em>Alcohol</em></p><p>Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by co-administration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to maximize the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7 g/kg or approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were observed. When tadalafil was administered with lower doses of alcohol (0.6 g/kg), hypotension was not observed and dizziness occurred with similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10 mg).</p><p><em>Cytochrome P450 metabolised medicinal products</em></p><p>Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of medicinal products metabolised by CYP450 isoforms. Tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.</p><p><em>CYP2C9 substrates (e.g. R-warfarin)</em></p><p>Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by warfarin.</p><p><em>Aspirin</em></p><p>Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid.</p><p><em>Antidiabetic medicinal products</em></p><p>Specific interaction studies with antidiabetic medicinal products were not conducted.</p><p>ions (mean maximum blood concentration 0.08%) were not affected by co-administration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to maximize the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7 g/kg or approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were observed. When tadalafil was administered with lower doses of alcohol (0.6 g/kg), hypotension was not observed and dizziness occurred with similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10 mg).</p><p><em>Cytochrome P450 metabolised medicinal products</em></p><p>Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of medicinal products metabolised by CYP450 isoforms. Tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.</p><p><em>CYP2C9 substrates (e.g. R-warfarin)</em></p><p>Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by warfarin.</p><p><em>Aspirin</em></p><p>Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid.</p><p><em>Antidiabetic medicinal products</em></p><p>Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil is not indicated for use by women.</p><p><u>Pregnancy</u></p><p>There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy<strong><em>,&nbsp;</em></strong>embryonic/fetal development, parturition or postnatal development. As a precautionary measure, it is preferable to avoid the use of tadalafil during pregnancy.</p><p><u>Breastfeeding</u></p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk. A risk to the suckling child cannot be excluded. Tadalafil should not be used during breast feeding.</p><p><u>Fertility</u></p><p>Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in some men.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil has negligible influence on the ability to drive or use machines. Patients should be aware of how they react to tadalafil before driving or using machines.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil. The adverse reactions reported were transient, and generally mild or moderate. The majority of headaches reported with tadalafil once-a-day dosing are experienced within the first 10 to 30 days of starting treatment.</p><p><u>Tabulated summary of adverse reactions</u></p><p>The table below lists the adverse reactions observed for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day treatment of benign prostatic hyperplasia.</p><p>Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000) and Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td><td style="vertical-align:top"><p>Angioedema<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Stroke<sup>1&nbsp;</sup>(including hemorrhagic events), Syncope, Transient ischaemic attacks<sup>1</sup>, Migraine<sup>2</sup>, Seizures<sup>2</sup>, Transient amnesia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blurred vision, Sensations described as eye pain</p></td><td style="vertical-align:top"><p>Visual field defect, Swelling of eyelids, Conjunctival hyperemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)<sup>2</sup>, Retinal vascular occlusion<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Sudden hearing loss</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Cardiac disorders<sup>1</sup></em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Myocardial infarction, Unstable angina pectoris<sup>2</sup>, Ventricular arrhythmia<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension<sup>3</sup>, Hypertension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Abdominal pain, Vomiting, Nausea, Gastro-oesophageal reflux</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, Stevens-Johnson syndrome<sup>2</sup>, Exfoliative dermatitis<sup>2</sup>, Hyperhydrosis (sweating)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Musculoskeletal, connective tissue and bone disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Back pain, Myalgia, Pain in extremity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Prolonged erections</p></td><td style="vertical-align:top"><p>Priapism, Penile hemorrhage, Hematospermia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Chest pain<sup>1</sup>, Peripheral oedema, Fatigue</p></td><td style="vertical-align:top"><p>Facial oedema<sup>2</sup>, Sudden cardiac death<sup>1,2</sup></p></td></tr></tbody></table><p>(1) Most of the patients had pre-existing cardiovascular risk factors.</p><p>(2) Post marketing surveillance reported adverse reactions.</p><p>(3) More commonly reported when tadalafil is given to patients who are already taking antihypertensive medicinal products.</p><p><u>Description of selected adverse reactions</u></p><p>A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in patients treated with tadalafil once a day as compared with placebo. Most of these ECG abnormalities were not associated with adverse reactions.</p><p><u>Other special populations</u></p><p>Data in patients over 65 years of age receiving tadalafil, either for the treatment of erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. Tadalafil taken on demand for the treatment of erectile dysfunction, diarrhoea was reported more frequently in patients over 65 years of age. Tadalafil taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years of age.</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone : 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>-&nbsp;&nbsp;&nbsp; <strong>Other GCC States: </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses up to 100 mg have been given to patients. Adverse events were similar to those seen at lower doses.</p><p>In cases of overdose, standard supportive measures should be adopted, as required. Hemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Urological, Drugs used in erectile dysfunction<strong>. ATC code:</strong> G04BE08.</p><p><u>Mechanism of action</u></p><p>Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the treatment of erectile dysfunction in the absence of sexual stimulation.</p><p>Tadalafil 5 mg - The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced. These vascular effects may be complemented by inhibition of bladder afferent nerve activity and smooth muscle relaxation of the prostate and bladder.</p><p><u>Pharmacodynamic&nbsp;effects</u></p><p>Tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5 than on other phosphodiesterase. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels, liver, and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac contractility. Additionally, tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for photo-transduction. Tadalafil is also &gt;10,000-fold more potent for PDE5 than for PDE7 through PDE10.</p><p><em>Clinical efficacy and safety</em></p><p>Tadalafil administered to healthy subjects produced no significant difference compared to placebo in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg, respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of 0.2/4.6mmHg, respectively), and no significant change in heart rate.</p><p>No impairment of colour discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent with the low affinity of tadalafil for PDE6 compared to PDE5. Reports of changes in colour vision were rare (&lt;0.1%).</p><p>In men spermatogenesis decreases were observed in sperm count and concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not associated with changes in other parameters, such as motility, morphology, and FSH.</p><p><em>Erectile dysfunction</em></p><p>Tadalafil demonstrated statistically significant improvement in erectile function and the ability to have successful sexual intercourse up to 36 hours following dosing, as well as patients&#39; ability to attain and maintain erections for successful intercourse compared to placebo as early as 16 minutes following dosing.</p><p>In patients with erectile dysfunction secondary to spinal cord injury, tadalafil significantly improved the erectile function.</p><p>Tadalafil at doses of 2 to 100mg has been evaluated including patients with erectile dysfunction of various severities (mild, moderate, severe), etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction of at least 1 year in duration.</p><p>Most patient&rsquo;s responders to previous on-demand treatment with PDE5 inhibitors. Patients who were treatment-naive to PDE5 inhibitors were randomised to tadalafil 5mg once a day successful sexual intercourse attempts was 68% for tadalafil patients.</p><p><em>Benign prostatic hyperplasia</em></p><p>The improvements in total international prostate symptom score occurred as early as 1 week</p><p>The improvements in the erectile function domain of the international index of erectile function and the total international prostate symptom score in successful sexual intercourse attempts was 71.9% with tadalafil 5 mg showed that the improvement in total international prostate symptom score seen at 12 weeks was maintained for up to 1 additional year of treatment with tadalafil 5mg.</p><p><em>Paediatric population</em></p><p>A single study has been performed in paediatric patients with Duchenne Muscular Dystrophy (DMD) in which no evidence of efficacy was seen. The randomised, double&ndash;blind, placebo&ndash;controlled, parallel, 3&ndash;arm study of tadalafil was conducted in 331 boys aged 7&ndash;14 years with DMD receiving concurrent corticosteroid therapy. The study included a 48&ndash;week double-blind period where patients were randomised to tadalafil 0.3 mg/kg, tadalafil 0.6 mg/kg, or placebo daily. Tadalafil did not show efficacy in slowing the decline in ambulation as measured by the primary 6 minute walk distance (6MWD) endpoint: least squares (LS) mean change in 6MWD at 48 weeks was &ndash;51.0 meters (m) in the placebo group, compared with &ndash;64.7 m in the tadalafil 0.3 mg/kg group (p = 0.307) and &ndash;59.1 m in the tadalafil 0.6 mg/kg group (p = 0.538). In addition, there was no evidence of efficacy from any of the secondary analyses performed in this study. The overall safety results from this study were generally consistent with the known safety profile of tadalafil and with adverse events (AEs) expected in a paediatric DMD population receiving corticosteroids</p><p>The European Medicines Agency has waived the obligation to submit the results of studies in all subsets of the paediatric population in the treatment of the erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma concentration (C<sub>max</sub>) is achieved at a median time of 2 hours after dosing. Absolute bioavailability of tadalafil following oral dosing has not been determined.</p><p>The rate and extent of absorption of tadalafil are not influenced by food, thus tadalafil may be taken with or without food. The time of dosing (morning versus evening) had no clinically relevant effects on the rate and extent of absorption.</p><p><u>Distribution</u></p><p>The mean volume of distribution is approximately 63 l, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. Protein binding is not affected by impaired renal function.</p><p>Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.</p><p><u>Biotransformation</u></p><p>Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major circulating metabolite is the methyl catechol glucuronide. This metabolite is at least 13,000-fold less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at observed metabolite concentrations.</p><p><u>Elimination</u></p><p>The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy subjects.</p><p>Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).</p><p><u>Linearity/Non-Linearity</u></p><p>Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steady-state plasma concentrations are attained within 5 days of once daily dosing.</p><p>Pharmacokinetics determined with a population approach in patients with erectile dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction.</p><p><u>Special Populations</u></p><p><em>Elderly</em></p><p>Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is not clinically significant and does not warrant a dose adjustment.</p><p><em>Renal Insufficiency</em></p><p>In hemodialysis patients, C<sub>max</sub>&nbsp;was 41% higher than that observed in healthy subjects. Hemodialysis contributes negligibly to tadalafil elimination.</p><p><em>Hepatic Insufficiency</em></p><p>There is limited clinical data on the safety of tadalafil in patients with severe hepatic insufficiency (Child-Pugh class C). If tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of once-a-day dosing of tadalafil to patients with hepatic impairment. If tadalafil is prescribed once-a-day, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment.</p><p><em>Patients with Diabetes</em></p><p>Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate,</p><p>Crosscarmellose Sodium,</p><p>Hydroxypropylcellulose,</p><p>Sodium Lauryl Sulphate,</p><p>Microcrystalline Cellulose,</p><p>Magnesium Stearate,</p><p>Opadry White,</p><p>Red Iron Oxide &amp;</p><p>Yellow Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Edyst<sup>&reg;</sup> 20mg F.C. Tablets </strong>are packed in Aluminum foil, PVC/ Aclar/ PVC blisters, with a multi folded leaflet packed in registration box.</p><p><strong>Pack sizes:</strong></p><p>4 tablets / blister, one blister/ pack &amp;</p><p>One tablet/ blister, one blister/ pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The United Pharmaceutical Mfg. Co. Ltd.
P.O. Box 69, Amman 11591-Jordan
Tel: + 962 (6) 416 2901      
Fax: + 962 (6) 416 2905 
E-mail:  Info@upm.com.jo

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July, 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>